IBI110,Sintilimab
eli lilly,Innovent Biologics
['ibi110', 'innovent']
innovent presents phase 1b clinical data of ibi110 (anti-lag-3 monoclonal antibody) at the 2023 asco annual meeting 
To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people.